Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of luseogliflozin in type 2 diabetes mellitus with hepatic dysfunction
jRCTs021180017Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luseogliflozin in type 2 diabetes mellitus (T2DM), hepatic disease and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in hepatic enzymes and HbA1c at 52 weeks. Started Apr 2017; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hepatic diseasemetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs021180017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180017.